Findings from the IMPLEMENT sub-analysis investigating sufferers with metastatic castration-sensitive prostate most cancers present variations in remedy intensification adoption between tutorial and nonacademic...
Sufferers with intermediate-risk prostate most cancers had a 15-year prostate most cancers–particular survival price of 91% with EBRT, with or with out short-term...